Trocmé Candice, Gonnet Nicolas, Di Tommaso Margaux, Samouda Hanen, Cracowski Jean-Luc, Cracowski Claire, Lambert-Porcheron Stéphanie, Laville Martine, Nobécourt Estelle, Gaddhab Chiraz, Le Lay Allan, Bohn Torsten, Poitou Christine, Clément Karine, Al-Mulla Fahd, Bitar Milad S, Bottari Serge P
Department of Biochemistry, Molecular Biology and Environmental Toxicology, Centre Hospitalier Grenoble-Alpes, La Tronche, France.
Centre d'Investigation Clinique, Centre Hospitalier Grenoble-Alpes, La Tronche, France.
Front Mol Biosci. 2021 Feb 16;7:596141. doi: 10.3389/fmolb.2020.596141. eCollection 2020.
Insulin resistance (IR), currently called prediabetes (PD), affects more than half of the adult population worldwide. Type 2 diabetes (T2D), which often follows in the absence of treatment, affects more than 475 million people and represents 10-20% of the health budget in industrialized countries. A preventive public health policy is urgently needed in order to stop this constantly progressing epidemic. Indeed, early management of prediabetes does not only strongly reduce its evolution toward T2D but also strongly reduces the appearance of cardiovascular comorbidity as well as that of associated cancers. There is however currently no simple and reliable test available for the diagnosis or screening of prediabetes and it is generally estimated that 20-60% of diabetics are not diagnosed. We therefore developed an ELISA for the quantitative determination of serum Insulin-Regulated AminoPeptidase (IRAP). IRAP is associated with and translocated in a stoechiometric fashion to the plasma membrane together with GLUT4 in response to insulin in skeletal muscle and adipose tissue which are the two major glucose storage sites. Its extracellular domain (IRAPs) is subsequently cleaved and secreted in the blood stream. In T2D, IRAP translocation in response to insulin is strongly decreased. Our patented sandwich ELISA is highly sensitive (≥10.000-fold "normal" fasting concentrations) and specific, robust and very cost-effective. Dispersion of fasting plasma concentration values in a healthy population is very low (101.4 ± 15.9 μg/ml) as compared to those of insulin (21-181 pmol/l) and C-peptide (0.4-1.7 nmol/l). Results of pilot studies indicate a clear correlation between IRAPs levels and insulin sensitivity. We therefore think that plasma IRAPs may be a direct marker of insulin sensitivity and that the quantitative determination of its plasma levels should allow large-scale screening of populations at risk for PD and T2D, thereby allow the enforcement of a preventive health policy aiming at efficiently reducing this epidemic.
胰岛素抵抗(IR),目前被称为糖尿病前期(PD),影响着全球超过一半的成年人口。2型糖尿病(T2D)若不治疗往往接踵而至,影响着超过4.75亿人,在工业化国家占卫生预算的10 - 20%。迫切需要一项预防性公共卫生政策来阻止这一不断发展的流行病。事实上,糖尿病前期的早期管理不仅能大幅降低其向T2D的进展,还能显著减少心血管合并症以及相关癌症的出现。然而,目前尚无简单可靠的检测方法用于糖尿病前期的诊断或筛查,一般估计有20 - 60%的糖尿病患者未被诊断出来。因此,我们开发了一种用于定量测定血清胰岛素调节氨肽酶(IRAP)的酶联免疫吸附测定(ELISA)法。在骨骼肌和脂肪组织(这两个主要的葡萄糖储存部位)中,IRAP与葡萄糖转运蛋白4(GLUT4)一起,在胰岛素作用下以化学计量方式与质膜结合并转位。其细胞外结构域(IRAPs)随后被切割并分泌到血流中。在T2D中,胰岛素刺激下的IRAP转位显著减少。我们获得专利的夹心ELISA法高度灵敏(≥正常空腹浓度的10000倍)、特异、稳健且性价比极高。与胰岛素(21 - 181 pmol/l)和C肽(0.4 - 1.7 nmol/l)相比,健康人群空腹血浆浓度值的离散度非常低(101.4 ± 15.9 μg/ml)。初步研究结果表明IRAPs水平与胰岛素敏感性之间存在明显相关性。因此,我们认为血浆IRAPs可能是胰岛素敏感性的直接标志物,对其血浆水平进行定量测定应能对糖尿病前期和T2D高危人群进行大规模筛查,从而实施旨在有效减少这一流行病的预防性健康政策。